AI Engines For more Details: Perplexity Kagi Labs You
Chemotherapy-Induced Nausea and Vomiting (CINV): Dolasetron mesilate is indicated for the prevention and treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients undergoing cancer chemotherapy. It works by blocking serotonin (5-HT3) receptors in the chemoreceptor trigger zone (CTZ) and gastrointestinal tract, thereby reducing the emetogenic effects of chemotherapy agents.
Postoperative Nausea and Vomiting (PONV): Dolasetron mesilate is also used to prevent postoperative nausea and vomiting (PONV) in patients undergoing surgical procedures where PONV is expected. It helps reduce the incidence and severity of nausea and vomiting during the immediate postoperative period.
Radiation-Induced Nausea and Vomiting: Dolasetron mesilate may be used off-label to prevent nausea and vomiting associated with radiation therapy. It has shown efficacy in reducing the frequency and severity of radiation-induced emesis when administered prophylactically.
Hyperemesis Gravidarum (Off-label Use): In some cases, dolasetron mesilate may be prescribed off-label for the management of severe nausea and vomiting of pregnancy, including hyperemesis gravidarum. However, its use in pregnant women is generally limited due to concerns about potential fetal safety.
Other Indications (Off-label Use): Dolasetron mesilate has been investigated for its potential efficacy in other conditions associated with nausea and vomiting, such as migraine-associated nausea and vomiting, cyclic vomiting syndrome, and motion sickness. However, its use in these conditions is not well-established, and further research is needed to determine its effectiveness and safety.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.5 | 0.3 | 0.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergy to milk products | 0.3 | 0.3 | |
| Alzheimer's disease | 0.8 | -0.8 | |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.5 | 0.5 | 0 |
| Atherosclerosis | 0.6 | -0.6 | |
| Atrial fibrillation | 0.3 | 0.3 | |
| Autism | 0.8 | 0.8 | 0 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Bipolar Disorder | 0.8 | -0.8 | |
| Brain Trauma | 0.5 | -0.5 | |
| Breast Cancer | 0.3 | 0.3 | |
| Celiac Disease | 0 | 0 | |
| Cerebral Palsy | 0.5 | -0.5 | |
| Chronic Fatigue Syndrome | 0.7 | -0.7 | |
| Chronic Kidney Disease | 0.8 | -0.8 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.5 | 0.5 | 0 |
| Colorectal Cancer | 0.5 | 0.5 | 0 |
| Constipation | 0.5 | -0.5 | |
| Coronary artery disease | 0.8 | -0.8 | |
| COVID-19 | 0.8 | -0.8 | |
| Crohn's Disease | 0.8 | 0.8 | 0 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.8 | 0.5 | 0.6 |
| Depression | 0.8 | 1.3 | -0.63 |
| Endometriosis | 0.3 | 0.8 | -1.67 |
| Fibromyalgia | 0.5 | 0.5 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.8 | -1.67 |
| gallstone disease (gsd) | 0.5 | -0.5 | |
| Generalized anxiety disorder | 0.3 | 0.8 | -1.67 |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 0.8 | -0.8 | |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.5 | 0.5 | |
| Heart Failure | 0.3 | 0.5 | -0.67 |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypertension (High Blood Pressure | 0.8 | -0.8 | |
| Hypothyroidism | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 0.8 | -0.8 | |
| Insomnia | 0.3 | 0.5 | -0.67 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.3 | -0.3 | |
| Irritable Bowel Syndrome | 0.5 | 0.8 | -0.6 |
| ischemic stroke | 0.5 | -0.5 | |
| Liver Cirrhosis | 0.8 | 0.8 | 0 |
| Long COVID | 0.5 | 0.8 | -0.6 |
| Low bone mineral density | 0.8 | -0.8 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.5 | -0.5 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 0.8 | 0.8 | 0 |
| Mood Disorders | 0.8 | 1.3 | -0.63 |
| Multiple Sclerosis | 0.8 | -0.8 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.5 | -0.5 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.8 | -0.6 |
| Obesity | 0.8 | 0.8 | 0 |
| obsessive-compulsive disorder | 0.3 | -0.3 | |
| Osteoporosis | 0.5 | 0.5 | |
| Parkinson's Disease | 0.8 | 0.8 | 0 |
| Polycystic ovary syndrome | 0.8 | 0.5 | 0.6 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | -0.3 | |
| Psoriasis | 0.8 | -0.8 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0.8 | 0 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.3 | 0.8 | -1.67 |
| scoliosis | 0.3 | 0.3 | |
| Sleep Apnea | 0.3 | 0.8 | -1.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.8 | -0.6 |
| Systemic Lupus Erythematosus | 0.3 | 0.5 | -0.67 |
| Type 1 Diabetes | 0.3 | 0.5 | -0.67 |
| Type 2 Diabetes | 0.8 | 0.8 | 0 |
| Ulcerative colitis | 0.8 | -0.8 | |
| Unhealthy Ageing | 0.3 | 0.8 | -1.67 |
| Vitiligo | 0.5 | -0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
